CAR-TCR Summit Europe 2021 | CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS

David Gilham, PhD, Celyad Oncology, Mont-Saint-Guibert, Belgium, describes the ongoing Phase 1 CYCLE-1 dose-escalation study (NCT04167696) of CYAD-02, an investigational autologous CAR-T cell therapy that is engineered to express both the natural killer group 2D (NKG2D) receptor and short hairpin RNA (shRNA), in patients with relapsed/refractory acute myeloid leukemia (r/r AML) or myelodysplastic syndrome (MDS). This study aims to determine the recommended dose of CYAD-02 and evaluate safety and clinical activity of a single infusion of CYAD-02 following preconditioning chemotherapy in patients with r/r AML or MDS. This interview took place during the CAR-TCR Summit Europe 2021.